Recommendations for the treatment of fungal pneumonias

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.4.8.1241PMID 12877634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

  2020cited by this paper
• Caspofungin

  2012cited by this paper
• Serology of coccidioidomycosis

  2005cited by this paper
• Current Topic : Fungal Infections Vol . 16 , No . 1 Eur

  2005cited by this paper
• Penicillium marneffei: types and drug susceptibility

  2004cited by this paper
• Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

  2003cited by this paper
• Caspofungin Acetate for Treatment of Invasive Fungal Infections

  2003cited by this paper
• Voriconazole: A New Triazole Antifungal Agent

  2003cited by this paper
• Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men

  2002cited by this paper
• Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens

  2002cited by this paper
• Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.

  2002cited by this paper
• Antifungal use in HIV infection

  2002influential reference
• Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  2002cited by this paper
• A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship

  2002cited by this paper
• Caspofungin: an echinocandin antifungal agent.

  2002cited by this paper
• Review of the safety and efficacy of voriconazole

  2002cited by this paper
• Overview of the lipid formulations of amphotericin B.

  2002cited by this paper
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.

  2002cited by this paper
• New antifungal agents.

  2002cited by this paper
• Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia

  2002cited by this paper
• In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.

  2002cited by this paper
• Amphotericin B nephrotoxicity.

  2002cited by this paper
• Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.

  2002cited by this paper
• New antifungal agents.

  2002cited by this paper
• A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

  2002cited by this paper
• Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin

  2002cited by this paper
• Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

  2002cited by this paper
• Safety and tolerability of caspofungin acetate in the treatment of fungal infections

  2002cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan.

  2002cited by this paper
• Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes

  2002cited by this paper
• Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

  2002cited by this paper
• Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

  2002cited by this paper
• Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors.

  2001cited by this paper
• International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program

  2001cited by this paper
• Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.

  2001cited by this paper
• Caspofungin acetate: an antifungal agent.

  2001cited by this paper
• A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

  2000cited by this paper
• Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina.

  2000cited by this paper
• Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America.

  2000cited by this paper
• Practice Guidelines for Diseases Caused by Aspergillus

  2000influential reference
• Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases.

  2000cited by this paper
• In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

  2000cited by this paper
• Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis

  2000cited by this paper
• A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.

  2000cited by this paper
• Fungal pneumonias.

  2000influential reference
• Practice Guidelines for the Treatment of Coccidioidomycosis

  2000influential reference
• Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

  2000cited by this paper
• Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America.

  2000cited by this paper
• Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis

  2000cited by this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000influential reference
• A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.

  2000cited by this paper
• Relationship between Mutations in Dihydropteroate Synthase of Pneumocystis carinii f. sp.hominis Isolates in Japan and Resistance to Sulfonamide Therapy

  2000cited by this paper
• Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America.

  2000influential reference
• Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America.

  2000influential reference
• A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia

  2000cited by this paper
• Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

  2000influential reference
• Introduction to antifungal drugs.

  2000cited by this paper
• Clinical Utility of Monitoring Serum Cryptococcal Antigen (sCRAG) Titers in Patients with AIDS-Related Cryptococcal Disease

  2000cited by this paper
• Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability

  1999cited by this paper
• Integrons and gene cassettes: a genetic construction kit for bacteria.

  1999cited by this paper
• Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

  1999cited by this paper
• Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.

  1999cited by this paper
• Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole.

  1999influential reference
• Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.

  1999cited by this paper
• Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens

  1999cited by this paper
• International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

  1999cited by this paper
• In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa

  1999cited by this paper
• Amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia.

  1999cited by this paper
• In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa

  1999cited by this paper
• Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

  1998cited by this paper
• Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients.

  1998cited by this paper
• Current and future therapy of invasive fungal infections.

  1998cited by this paper
• Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.

  1998cited by this paper
• Paracoccidioidomycosis and AIDS: report of the first two Colombian cases.

  1998cited by this paper
• Use of Fiberoptic Bronchoscopy in Bone Marrow Transplant Recipients

  1998cited by this paper
• Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors.

  1998cited by this paper
• In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

  1998cited by this paper
• In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?

  1998cited by this paper
• Lipid formulations of amphotericin B: clinical efficacy and toxicities.

  1998cited by this paper
• Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

  1998cited by this paper
• Predictors of adverse outcome in cancer patients with candidemia.

  1998cited by this paper
• In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.

  1998cited by this paper
• Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

  1998cited by this paper
• Current and future therapy of invasive fungal infections.

  1998cited by this paper
• Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.

  1997cited by this paper
• International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

  1997cited by this paper
• The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

  1997cited by this paper
• In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates

  1997cited by this paper
• In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

  1997cited by this paper
• Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS‐associated cryptococcal meningitis

  1997cited by this paper
• Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings.

  1997cited by this paper
• Therapeutic outcome in invasive aspergillosis.

  1996cited by this paper
• Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases.

  1996cited by this paper
• Quandary about treatment of aspergillomas persists.

  1996cited by this paper
• Coccidioidomycosis--Arizona, 1990-1995.

  1996cited by this paper
• Fluconazole monotherapy for cryptococcosis in non-AIDS patients

  1996cited by this paper
• Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study.

  1996cited by this paper
• Pneumocystis carinii: what is it, exactly?

  1996cited by this paper

• Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity

  2013cites this paper
• Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical

  2012cites this paper
• CHAPTER 27 – Fungal infections of the respiratory tract

  2009cites this paper
• Thoracic and Pulmonary Infections

  2008cites this paper
• Case Report Pulmonary Coccidioides nodule in a Swiss patient with chronic lymphatic leukaemia

  2008cites this paper
• Pulmonary Coccidioides nodule in a Swiss patient with chronic lymphatic leukaemia.

  2008cites this paper
• Chapter 19 – Systemic fungal infections

  2006cites this paper
• A young man who could not walk.

  2006cites this paper
• Drugs Acting on Infectious Organisms

  2006cites this paper
• Nosocomial pulmonary infections in HIV-positive patients

  2005cites this paper
• Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin

  2002cites this paper